Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

SP46. Anatomic Analysis of a Masseteric to Zygomatic Nerve Transfer in Rat and Pig Models
Millesi, Elena , Suchyta, Marissa , Wang, Huang, Mardini, Samir

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 18, 2023 | Volume: 11 | Issue: 5S | Pages: 148-149

10.1097/01.gox.0000938528.13345.90 Get It

A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
Veeraraghavan, Jamunarani , Gutiérrez, Carolina , Angelis, Carmine De , Davis, Robert , Wang, Tao , Pascual, Tomás , Selenica, Pier , Sanchez, Katherine , Nitta, Hiroaki , Kapadia, Monesh , Pavlick, Anne C. , Rexer, Brent N. , Forero-Torres, Andres , Nanda, Rita , Storniolo, Anna Maria , Krop, Ian E. , Nangia, Julie R. , Weigelt, Britta , Prat, Aleix , Osborne, C. Kent , Rimawi, Mothaffar F. , De Angelis, Carmine , Galvan, Patricia , Rexer, Brent , Forero-Torres, Andres , Nanda, Rita , Storniolo, Anna M , Krop, Ian E , Goetz, Matthew P , Nangia, Julie R , Wolff, Antonio C , Weigelt, Britta , Reis-Filho, Jorge S , Hilsenbeck, Susan Galloway , Prat, Aleix , Osborne, C Kent , Schiff, Rachel , Rimawi, Mothaffar , Wang, Tao , Goetz, Matthew P. , Wolff, Antonio C. , Reis‐Filho, Jorge S. , Schiff, Rachel

Mayo Clinic

Clinical Cancer Research | May 17, 2023 | Volume: 29 | Issue: 16 | Pages: 3101-3109

10.1158/1078-0432.ccr-22-3753 | PMID 37195235 Get It

Abstract Purpose: Clinical trials reported 25% to 30% pathologic complete response (pCR) rates in HER2+ patients with breast cancer treated with anti-HER2 therapies without chemotherapy. We hypothesize that a multiparameter classifier can identify patients with HER2-“addicted” tumors who may benefit from a chemotherapy-sparing strategy. Experimental Design: Baseline HER2+ breast cancer specimens from the TBCRC023 and PAMELA trials, which included neoadjuvant treatment with lapatinib and trastuzumab, were used. In the case of estrogen receptor–positive (ER+) tumors, endocrine therapy was also administered. HER2 protein and gene amplification (ratio), HER2-enriched (HER2-E), and PIK3CA mutation status were assessed by dual gene protein assay (GPA), research-based PAM50, and targeted DNA-sequencing. GPA cutoffs and classifier of response were constructed in TBCRC023 using a decision tree algorithm, then validated in PAMELA. Results: In TBCRC023, 72 breast cancer specimens had GPA, PAM50, and sequencing data, of which 15 had pCR. Recursive partitioning identified cutoffs of HER2 ratio ≥ 4.6 and %3+ IHC staining ≥ 97.5%. With PAM50 and sequencing data, the model added HER2-E and PIK3CA wild-type (WT). For clinical implementation, the classifier was locked as HER2 ratio ≥ 4.5, %3+ IHC staining ≥ 90%, and PIK3CA-WT and HER2-E, yielding 55% and 94% positive (PPV) and negative (NPV) predictive values, respectively. Independent validation using 44 PAMELA cases with all three biomarkers yielded 47% PPV and 82% NPV. Importantly, our classifier's high NPV signifies its strength in accurately identifying patients who may not be good candidates for treatment deescalation. Conclusions: Our multiparameter classifier differentially identifies patients who may benefit from HER2-targeted therapy alone from those who need chemotherapy and predicts pCR to anti-HER2 therapy alone comparable with chemotherapy plus dual anti-HER2 therapy in unselected patients.
The Alzheimer's Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge: Results after 1 Year Follow-up
Bron, Esther E. , Toga, Arthur W. , Weiner, Michael W. , Barkhof, Frederik , Fox, Nick C. , Eshaghi, Arman , Toni, Tina, Salaterski, Marcin, Lunina, Veronika, Ansart, Manon , Lu, Pascal , Thompson, Wesley K., Nahon, Aviv, Levy, Yarden, Halbersberg, Dan, Cohen, Mariya, Liao, Huiling , Yu, Kaixian , Ismail, Aya, Wood, Timothy C. , Nguyen, Minh , Sun, Nanbo , Yeo, B.T. Thomas , Qi, Ke , Chen, Shiyang , Qiu, Deqiang , Buciuman, Ionut, Kelner, Alex, Rimocea, Denisa, Ourselin, Sébastien , Venkatraghavan, Vikram , Liu, Keli , Rabe, Christina, Manser, Paul T. , Howlett, James , Huang, Zhiyue , Mukherjee, Sach, Rouanet, Anaïs , Oriol, Javier de Velasco , Clemente, Edgar E. V., Estrada, Karol , Altmann, André , Stonnington, Cynthia M. , Wu, Jianfeng , Devadas, Vivek, Fourrier, Clémentine , Doshi, Jimit , Moore, Paul J. , Lyons, Terry , Ciszek, Robert, Jedynak, Bruno , Pandya, K., Engels, William R., Cole, Joseph B., Golland, Polina , Alexander, Daniel C. , Initiative, The Alzheimer's Disease Neuroimaging, Toga, Arthur W , Barkhof, Frederik , Fox, Nick C , Weiner, Michael W , Marinescu, Razvan Valentin , Oxtoby, Neil P. , Young, Alexandra L. , Durrleman, Stanley , Iddi, Samuel , Li, Dan , Donohue, Michael , Li, Tengfei , Zhu, Hongtu , Tamez‐Peña, José G. , Wood, Timothy, Bravo, Héctor Corrada , Feng, Jiashi , Chen, Gang , Qi, Ke, Pop, Raluca, Ghazi, Mostafa Mehdipour , Nielsen, Mads , Sørensen, Lauge , Hill, Steven M., Kiddle, Steven John , Taschler, Bernd , Tom, Brian D. M. , White, Simon Richard , Faux, Noel Garry , Sedai, Suman , Aksman, Leon , Wang, Yalin , Rakêt, Lars Lau , Sotiras, Aristeidis , Erus, Güray , Davatzikos, Christos , Vogel, Jacob W. , Doyle, Andrew , Tam, Angela , Diaz-Papkovich, Alex , Jammeh, Emmanuel , Koval, Igor , Gallacher, John , Tohka, Jussi , Pandya, Kruti, Bilgel, Murat , Engels, William, Cole, Joseph, Klein, Stefan , Initiative, The Alzheimer's Disease Neuroimaging

Mayo Clinic

Machine Learning for Biomedical Imaging | May 17, 2023 | Volume: 1 | Issue: December 2021 | Pages: 1-60

10.59275/j.melba.2021-2dcc Get It

Accurate prediction of progression in subjects at risk of Alzheimer's disease is crucial for enrolling the right subjects in clinical trials. However, a prospective comparison of state-of-the-art algorithms for predicting disease onset and progression is currently lacking. We present the findings of "The Alzheimer's Disease Prediction Of Longitudinal Evolution" (TADPOLE) Challenge, which compared the performance of 92 algorithms from 33 international teams at predicting the future trajectory of 219 individuals at risk of Alzheimer's disease. Challenge participants were required to make a prediction, for each month of a 5-year future time period, of three key outcomes: clinical diagnosis, Alzheimer's Disease Assessment Scale Cognitive Subdomain (ADAS-Cog13), and total volume of the ventricles. The methods used by challenge participants included multivariate linear regression, machine learning methods such as support vector machines and deep neural networks, as well as disease progression models. No single submission was best at predicting all three outcomes. For clinical diagnosis and ventricle volume prediction, the best algorithms strongly outperform simple baselines in predictive ability. However, for ADAS-Cog13 no single submitted prediction method was significantly better than random guesswork. Two ensemble methods based on taking the mean and median over all predictions, obtained top scores on almost all tasks. Better than average performance at diagnosis prediction was generally associated with the additional inclusion of features from cerebrospinal fluid (CSF) samples and diffusion tensor imaging (DTI). On the other hand, better performance at ventricle volume prediction was associated with inclusion of summary statistics, such as the slope or maxima/minima of patient-specific biomarkers. On a limited, cross-sectional subset of the data emulating clinical trials, performance of the best algorithms at predicting clinical diagnosis decreased only slightly (2 percentage points) compared to the full longitudinal dataset. The submission system remains open via the website https://tadpole.grand-challenge.org, while TADPOLE SHARE (https://tadpole-share.github.io/) collates code for submissions. TADPOLE's unique results suggest that current prediction algorithms provide sufficient accuracy to exploit biomarkers related to clinical diagnosis and ventricle volume, for cohort refinement in clinical trials for Alzheimer's disease. However, results call into question the usage of cognitive test scores for patient selection and as a primary endpoint in clinical trials.
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Wang, Michael , Jurczak, Wojciech , Zinzani, Pier Luigi , Eyre, Toby A. , Cheah, Chan Y. , Ujjani, Chaitra S. , Koh, Youngil , Izutsu, Koji , Gerson, James N. , Flinn, Ian W. , Alencar, Alvaro J. , Ma, Shuo , Lewis, David , Patel, Krish , Maddocks, Kami J. , Lamanna, Nicole , Nagai, Hirokazu, Hernandez‐Ilizaliturri, Francisco J. , Kumar, Anita , Fenske, Timothy S. , Seymour, John F. , Nair, Binoj C., Tsai, Donald E. , Balbas, Minna, Walgren, Richard A., Abada, Paolo, Wang, Chunxiao , Zhao, Junjie, Mato, Anthony R. , Shah, Nirav N. , Wang, Michael L , Flinn, Ian W , Tessoulin, Benoit , Alencar, Alvaro J , Ma, Shuo , Lewis, David , Lech-Maranda, Ewa , Rhodes, Joanna , Patel, Krish , Lamanna, Nicole , Wang, Yucai , Tam, Constantine S , Munir, Talha , Kumar, Anita , Fenske, Timothy S , Seymour, John F , Zelenetz, Andrew D , Abada, Paolo , Mato, Anthony , Shah, Nirav N , Zinzani, Pier Luigi , Cheah, Chan Yoon , Izutsu, Koji , Jurczak, Wojciech , Lech‐Marańda, Ewa , Rhodes, Joanna , Wang, Yucai , Tam, Constantine S. , Zelenetz, Andrew D.

Mayo Clinic

Journal of Clinical Oncology | May 16, 2023 | Volume: 41 | Issue: 24 | Pages: 3988-3997

10.1200/jco.23.00562 | PMID 37192437 Get It

PURPOSE Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (MCL), a population with poor prognosis. METHODS Patients with cBTKi pretreated relapsed/refractory (R/R) MCL received pirtobrutinib monotherapy in a multicenter phase I/II trial (BRUIN; ClinicalTrials.gov identifier: NCT03740529 ). Efficacy was assessed in the first 90 consecutively enrolled patients who met criteria for inclusion in the primary efficacy cohort. The primary end point was overall response rate (ORR). Secondary end points included duration of response (DOR) and safety. RESULTS The median patient age was 70 years (range, 46-87), the median prior lines of therapy was 3 (range, 1-8), 82.2% had discontinued a prior cBTKi because of disease progression, and 77.8% had intermediate- or high-risk simplified MCL International Prognostic Index score. The ORR was 57.8% (95% CI, 46.9 to 68.1), including 20.0% complete responses (n = 18). At a median follow-up of 12 months, the median DOR was 21.6 months (95% CI, 7.5 to not reached). The 6- and 12-month estimated DOR rates were 73.6% and 57.1%, respectively. In the MCL safety cohort (n = 164), the most common treatment-emergent adverse events (TEAEs) were fatigue (29.9%), diarrhea (21.3%), and dyspnea (16.5%). Grade ≥3 TEAEs of hemorrhage (3.7%) and atrial fibrillation/flutter (1.2%) were less common. Only 3% of patients discontinued pirtobrutinib because of a treatment-related adverse event. CONCLUSION Pirtobrutinib is a first-in-class novel noncovalent (reversible) BTKi and the first BTKi of any kind to demonstrate durable efficacy after prior cBTKi therapy in heavily pretreated R/R MCL. Pirtobrutinib was well tolerated with low rates of treatment discontinuation because of toxicity.
Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Wang, Qiao-Li , Ma, Chao , Yuan, Chen , Shi, Qian , Wolpin, Brian M. , Zhang, Yin , Fuchs, Charles S. , Meyer, Jeffrey , Zemla, Tyler , Cheng, En , Kumthekar, Priya , Guthrie, Katherine A. , Couture, Félix , Kuebler, Philip , Kumar, Pankaj , Tan, Benjamin , Krishnamurthi, Smitha , Goldberg, Richard M. , Blanke, Charles D. , Shields, Anthony F. , Meyerhardt, Jeffrey A. , Ng, Kimmie , Kuebler, J. Philip , Venook, Alan P , Shields, Anthony F , O'Reilly, Eileen M , Meyerhardt, Jeffrey A , Ng, Kimmie , Shi, Qian , Zemla, Tyler J , Yuan, Chen , Venook, Alan P. , O’Reilly, Eileen M. , Cheng, En

Mayo Clinic

Clinical Cancer Research | May 11, 2023 | Volume: 29 | Issue: 14 | Pages: 2621-2630

10.1158/1078-0432.ccr-23-0447 | PMID 37289007 Get It

Abstract Purpose: To assess whether higher plasma 25-hydroxyvitamin D [25(OH)D] is associated with improved outcomes in colon cancer and whether circulating inflammatory cytokines mediate such association. Experimental Design: Plasma samples were collected from 1,437 patients with stage III colon cancer enrolled in a phase III randomized clinical trial (CALGB/SWOG 80702) from 2010 to 2015, who were followed until 2020. Cox regressions were used to examine associations between plasma 25(OH)D and disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Mediation analysis was performed for circulating inflammatory biomarkers of C-reactive protein (CRP), IL6, and soluble TNF receptor 2 (sTNF-R2). Results: Vitamin D deficiency [25(OH)D <12 ng/mL] was present in 13% of total patients at baseline and in 32% of Black patients. Compared with deficiency, nondeficient vitamin D status (≥12 ng/mL) was significantly associated with improved DFS, OS, and TTR (all Plog-rank<0.05), with multivariable-adjusted HRs of 0.68 (95% confidence interval, 0.51–0.92) for DFS, 0.57 (0.40–0.80) for OS, and 0.71 (0.52–0.98) for TTR. A U-shaped dose–response pattern was observed for DFS and OS (both Pnonlinearity<0.05). The proportion of the association with survival that was mediated by sTNF-R2 was 10.6% (Pmediation = 0.04) for DFS and 11.8% (Pmediation = 0.05) for OS, whereas CRP and IL6 were not shown to be mediators. Plasma 25(OH)D was not associated with the occurrence of ≥ grade 2 adverse events. Conclusions: Nondeficient vitamin D is associated with improved outcomes in patients with stage III colon cancer, largely independent of circulation inflammations. A randomized trial is warranted to elucidate whether adjuvant vitamin D supplementation improves patient outcomes.
A new synthetic lethal strategy expands the application of PARP inhibitors/cisplatin
Wang, Jinrui , Billadeau, Daniel D. , Zheng, Ying , Jia, Da

Mayo Clinic

MedComm – Oncology | May 11, 2023 | Volume: 2 | Issue: 2 | Pages: No page available

10.1002/mog2.28 Get It

Socioeconomic and Racial/Ethnic Disparities in Perception of Health Status and Literacy in Spine Oncological Patients
Elsamadicy, Aladine A. , Wang, Chelsea, Craft, Samuel , Rajjoub, Rami , Pennington, Zach , Lo, Sheng-Fu Larry , Mendel, Ehud , Sciubba, Daniel M. , Pennington, Zach , Reeves, Benjamin C. , Sherman, Josiah , Koo, Andrew B. , Hersh, Andrew M. , Shin, John H.

Mayo Clinic

Spine | May 10, 2023 | Volume: 48 | Issue: 15 | Pages: 1107-1115

10.1097/brs.0000000000004712 | PMID 37163649 Get It

Study Design. A cross-sectional study was performed using the National Institutes of Health All of Us survey database. Objective. The aim of this study was to assess socioeconomic and racial disparities in the perception of personal health, health literacy, and healthcare access among spine oncology patients. Summary of Background Data. Racial, ethnic, and socioeconomic disparities in health literacy and perception of health status have been described for many disease processes. However, few studies have assessed the prevalence of these disparities among spine oncology patients. Methods. Adult spine oncology patients, identified using ICD-9/10-CM codes, were categorized by race/ethnicity: White/Caucasian (WC), Black/African-American (BAA), and Non-White Hispanic (NWH). Demographics and socioeconomic status were assessed. Questionnaire responses regarding baseline health status, perception of health status, health literacy, and barriers to healthcare were compared. Results. Of the 1,175 patients identified, 207 (17.6%) were BAA, 267 (22.7%) were NWH, and 701 (59.7%) were WC. Socioeconomic status varied among cohorts, with WC patients reporting higher levels of education (P<0.001), annual income greater than $50K (P<0.001), and home ownership (P<0.001). BAA and NWH patients reported greater rates of 7-day “Severe fatigue” (P<0.001) and “10/10 pain” (P<0.001) and lower rates of “Completely” able to perform everyday activities (P<0.001). WC patients had a higher response rate for “Excellent/Very Good” regarding their own general health (P<0.001) and quality (P<0.001). The WC cohort had a significantly higher proportion of patients responding “Never” when assessing difficulty understanding (P<0.001) and needing assistance with health materials (P<0.001). BAA and NWH were significantly less likely to report feeling “Extremely” confident with medical forms (P<0.001). BAA and NWH had significantly higher response rates to feeling “Somewhat Worried” about healthcare costs (P<0.001) and with delaying medical care given “Can’t Afford Co-pay” (P<0.001). Conclusion. We identified disparities in perception of health status, literacy, and access among spine oncology patients. Level of Evidence. 4
A field map updating algorithm to improve fat‐water spiral imaging
Chao, Tzu Cheng , Wang, Dinghui , Krishnamoorthy, Guruprasad , Pipe, James G.

Mayo Clinic

Magnetic Resonance in Medicine | May 10, 2023 | Volume: 90 | Issue: 3 | Pages: 1219-1227

10.1002/mrm.29697 | PMID 37158313 Get It

PurposeAn accurate field map is essential to separate fat and water signals in a dual‐echo chemical shift encoded spiral MRI scan. A rapid low‐resolution B0 map prescan is usually performed before each exam. Occasional inaccuracy in these field map estimates can lead to misclassification of the water and fat signals as well as blurring artifacts in the reconstruction. The present work proposes a self‐consistent model to evaluate residual field offsets according to the image data to improve the reconstruction quality and facilitate the scan efficiency.Theory and MethodsThe proposed method compares the phase differences of the two‐echo data after correcting for fat frequency offsets. A more accurate field map is approximated according to the phase discrepancies and improved image quality. Experiments were conducted with simulated off‐resonance on a numerical phantom, five volunteer head scans, and four volunteer abdominal scans for validation.ResultsThe initial reconstruction of the demonstrated examples exhibit blurring artifacts and misregistration of fat and water because of the inaccuracy of the field map. The proposed method updates the field map to amend the fat and water estimation and improve image quality.ConclusionsThis work presents a model to improve the quality of fat‐water imaging of the spiral MRI by estimating a better field map from the acquired data. It allows reducing the field map pre‐scans before each spiral scan under normal circumstances to increase scan efficiency.
A Surface-Based Federated Chow Test Model for Integrating APOE Status, Tau Deposition Measure, and Hippocampal Surface Morphometry
Wu, Jianfeng , Initiative, for the Alzheimer’s Disease Neuroimaging, Chen, Yanxi , Zhu, Wenhui , Reiman, Eric M. , Caselli, Richard J., Thompson, Paul M. , Wang, Junwen , Thompson, Paul M , Wang, Junwen , Initiative, for the Alzheimer’s Disease Neuroimaging, Su, Yi , Caselli, Richard J. , Chen, Kewei , Wang, Yalin

Mayo Clinic

Journal of Alzheimer's Disease | May 10, 2023 | Volume: 93 | Issue: 3 | Pages: 1153-1168

10.3233/jad-230034 | PMID 37182882 Get It

Background: Alzheimer’s disease (AD) is the most common type of age-related dementia, affecting 6.2 million people aged 65 or older according to CDC data. It is commonly agreed that discovering an effective AD diagnosis biomarker could have enormous public health benefits, potentially preventing or delaying up to 40% of dementia cases. Tau neurofibrillary tangles are the primary driver of downstream neurodegeneration and subsequent cognitive impairment in AD, resulting in structural deformations such as hippocampal atrophy that can be observed in magnetic resonance imaging (MRI) scans. Objective: To build a surface-based model to 1) detect differences between APOE subgroups in patterns of tau deposition and hippocampal atrophy, and 2) use the extracted surface-based features to predict cognitive decline. Methods: Using data obtained from different institutions, we develop a surface-based federated Chow test model to study the synergistic effects of APOE, a previously reported significant risk factor of AD, and tau on hippocampal surface morphometry. Results: We illustrate that the APOE-specific morphometry features correlate with AD progression and better predict future AD conversion than other MRI biomarkers. For example, a strong association between atrophy and abnormal tau was identified in hippocampal subregion cornu ammonis 1 (CA1 subfield) and subiculum in e4 homozygote cohort. Conclusion: Our model allows for identifying MRI biomarkers for AD and cognitive decline prediction and may uncover a corner of the neural mechanism of the influence of APOE and tau deposition on hippocampal morphology.
Upregulation of the ERRγ–VDAC1 axis underlies the molecular pathogenesis of pancreatitis
Chanda, Dipanjan , Thoudam, Themis , Sinam, Ibotombi Singh , Lim, Chae Won , Wang, Jiale , Lee, Kyeong‐Min , Ma, Jing , Saxena, Romil, Choi, Jinhyuk , Oh, Chang Joo , Lee, Hoyul , Jeon, Yong Hyun , Jung, Hoe‐Yune , Choi, Hueng‐Sik , Ji, Baoan , Liangpunsakul, Suthat , Lee, In‐Kyu , Wang, Jiale , Lee, Kyeong-Min , Ma, Jing , Oh, Chang Joo , Lee, Hoyul , Jung, Hoe-Yune , Choi, Hueng-Sik , Suh, Jae Myoung , Auwerx, Johan , Liangpunsakul, Suthat , Jeon, Jae-Han , Lee, In-Kyu , Kim, Myeongjin , Cho, Sung Jin , Park, Keun‐Gyu

Mayo Clinic

Proceedings of the National Academy of Sciences | May 8, 2023 | Volume: 120 | Issue: 20 | Pages: No page available

10.1073/pnas.2219644120 | PMID 37155882 Get It

Emerging evidence suggest that transcription factors play multiple roles in the development of pancreatitis, a necroinflammatory condition lacking specific therapy. Estrogen-related receptor γ (ERRγ), a pleiotropic transcription factor, has been reported to play a vital role in pancreatic acinar cell (PAC) homeostasis. However, the role of ERRγ in PAC dysfunction remains hitherto unknown. Here, we demonstrated in both mice models and human cohorts that pancreatitis is associated with an increase in ERRγ gene expression via activation of STAT3. Acinar-specific ERRγ haploinsufficiency or pharmacological inhibition of ERRγ significantly impaired the progression of pancreatitis both in vitro and in vivo. Using systematic transcriptomic analysis, we identified that voltage-dependent anion channel 1 (VDAC1) acts as a molecular mediator of ERRγ. Mechanistically, we showed that induction of ERRγ in cultured acinar cells and mouse pancreata enhanced VDAC1 expression by directly binding to specific site of the Vdac1 gene promoter and resulted in VDAC1 oligomerization. Notably, VDAC1, whose expression and oligomerization were dependent on ERRγ, modulates mitochondrial Ca 2+ and ROS levels. Inhibition of the ERRγ–VDAC1 axis could alleviate mitochondrial Ca 2+ accumulation, ROS formation and inhibit progression of pancreatitis. Using two different mouse models of pancreatitis, we showed that pharmacological blockade of ERRγ–VDAC1 pathway has therapeutic benefits in mitigating progression of pancreatitis. Likewise, using PRSS1 R122H -Tg mice to mimic human hereditary pancreatitis, we demonstrated that ERRγ inhibitor also alleviated pancreatitis. Our findings highlight the importance of ERRγ in pancreatitis progression and suggests its therapeutic intervention for prevention and treatment of pancreatitis.